Latest Headlines

31. BGI's COVID-19 Test Laboratory At The Airport Secures Route Between Ethiopia And China 9/6/2021

    From April to August 2021 , the BGI's COVID-19 testing lab helped 5,500 Chinese travelers fly safely from Addis Ababa Bole International Airport. In April, the BGI, in cooperation with Ethiopia Airlines, set up the "Huo-Yan" laboratory, a COVID-19 test laboratory, at the airport for passengers flying to China only flight was suspended.

32. Home Blood Collection Device Works For COVID Antibody Test 9/3/2021

    A device that could make it possible for patients to draw their own blood at home was successfully used to collect blood samples for measuring antibodies against SARS-CoV-2, the virus that causes COVID-19, researchers at the University of Washington School of Medicine in Seattle report.

33. NuProbe Global And Bionano To Co-Develop Products In Reproductive Health And Oncology Testing 9/1/2021

    NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, and Bionano Genomics, based in San Diego, California, have entered into a procurement and collaboration agreement, where NuProbe will integrate their Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA) technologies with Bionano's Saphyr system for research and product development in the fields of reproductive health and oncology liquid biopsies.

34. Todos Medical’s CLIA/CAP Lab Provista Completes Validation Of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test 9/1/2021

    Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Quidel Lyra Influenza A & B and the Lyra RSV & hMPV PCR kits into production alongside COVID PCR tests currently being run (together the “Provista Respiratory Panel”) and expects this new respiratory panel to be launched in September 2021.

35. Natera Announces The Validation And Launch Of The Prospera™ Heart Transplant Assessment Test 8/31/2021

    Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, today announced the validation and clinical availability of its Prospera Heart transplant assessment test for heart transplant recipients.

36. BC Platforms Launches Packaged End-To-End Solution For NGS Laboratories With Sentieon To Accelerate Adoption Of NGS Testing 8/31/2021

    BC Platforms (BCP), a global leader in healthcare data management and analytics and US-based Sentieon, a developer of highly optimized algorithms for bioinformatics applications, today announced the launch of its new integrated next generation sequencing (NGS) genetic analytics software, known as BC|GENOME X-10.

37. Microbiologics Launches SARS-CoV-2 Whole Virus Antigen Controls For Point-Of-Care COVID-19 Diagnostics 8/31/2021

    Microbiologics has launched a new SARS-CoV-2 quality control (QC) product designed for use with antigen point-of-care (POC) methods.

38. Vizgen Releases Commercial MERSCOPE Platform 8/30/2021

    Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program.

39. AnPac Bio’s USA Laboratory Receives Accreditation From The College Of American Pathologists 8/30/2021

    AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its Philadelphia, PA Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”).

40. Visby Medical7™ Receives FDA Clearance And CLIA Waiver At The Point Of Care For PCR Sexual Health Test 8/30/2021

    Visby Medical™ announced today that it has received a 510(k) clearance and was granted a waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) from the US Food and Drug Administration (FDA) to market its fast, single-use polymerase chain reaction (PCR) diagnostic test for the multiplexed detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV), using a self-collected vaginal swab.